Case Digest (A.M. No. MTJ-94-894)
Facts:
The case involves Mercury Drug Corporation (the petitioner), a pharmaceutical retailer, and the Commissioner of Internal Revenue (CIR) as respondent. Mercury Drug Corporation granted a 20% sales discount to qualified senior citizens pursuant to Republic Act No. 7432 during the taxable years April to December 1993 and January to December 1994. The petitioner claimed these discounts, amounting to P3,719,287.68 in 1993 and P35,500,593.44 in 1994, as deductions from its gross income and sought tax credits for these amounts as allowed under the law. The petitioner filed claims for tax refunds in the amounts of P2,417,536.00 (1993) and P23,075,386.00 (1994), which the CIR did not act upon. Consequently, petitioner filed a petition for review before the Court of Tax Appeals (CTA).
The CTA partially granted the petition, declaring null and void the Revenue Regulations that treated the 20% discount as a deduction rather than as a tax credit. However, the CTA disallowed part of the claim
Case Digest (A.M. No. MTJ-94-894)
Facts:
- Context and Legislative Background
- The case involves the interpretation of the term "acosta" in Section 4(a) of Republic Act No. 7432, which grants a 20% sales discount to senior citizens on medicines and allows private establishments to claim the cost as a tax credit.
- Actions of Mercury Drug Corporation (Petitioner)
- Mercury Drug Corporation granted the 20% senior citizen discount on medicines in 1993 and 1994.
- The total discounts for 1993 and 1994 claimed were approximately P3.7 million and P35.5 million respectively.
- Petitioner claimed these discounts as deductions from gross income and subsequently filed claims for tax refund with the Commissioner of Internal Revenue (CIR) for P2.4 million (1993) and P23 million (1994), based on the tax credit for the discounts.
- Court of Tax Appeals (CTA) Proceedings
- The CIR failed to act on the refund claims, prompting petitioner to file a petition with the CTA.
- On September 6, 2000, the CTA partially granted the petition, declaring Revenue Regulations No. 2-94 null and void regarding the treatment of the discounts as deductions instead of tax credits.
- CTA disallowed part of the refund claims for discrepancies in documentation: discounted amounts allowed were P2,989,930.43 (1993) and P7,393,094.28 (1994).
- For 1993, petitioner was entitled to a tax credit of approximately P1.7 million; the 1994 refund claim was denied due to a tax liability.
- CTA applied a formula calculating tax credit based on the acquisition cost (cost of sales/gross sales multiplied by the discount amount) rather than the full discount amount.
- Reconsideration and Further Proceedings
- Petitioner moved for partial reconsideration.
- CTA increased allowable tax credit to over P18 million for both years and granted the 1994 refund claim based on revised figures.
- Court of Appeals (CA) Decision
- The CA affirmed the CTA's interpretation that the tax credit should be based on the acquisition cost, as supported by prior decisions particularly Commissioner of Internal Revenue v. Elmas Drug Corporation.
- Petitioner's motion for reconsideration was denied.
- Supreme Court (SC) Petition and Arguments
- Petitioner filed a petition for review, asserting:
- Limiting tax credit to acquisition cost is an unconstitutional taking without just compensation.
- Forcing discounts without full reimbursement violates due process, being oppressive and confiscatory.
- The CA had an inconsistent interpretation of "acosta" but still affirmed CTA's ruling.
- The spirit and reason of the law should be considered to avoid injustice.
- Equal protection requires treatment similar to Mar-Tess Drug.
- Petitioner argued tax credit should include all direct and indirect costs, not just acquisition cost.
- Office of the Solicitor General (OSG) Position
- Supported petitioner’s position that tax credit should be based on discounts properly substantiated.
- Cited Bicolandia Drug Corporation v. Commissioner of Internal Revenue ruling affirming that the 20% discount amount should be applied as tax credit.
- Supreme Court Findings
- The term "acosta" is interpreted as the actual amount of the 20% discount extended to senior citizens, not merely acquisition cost.
- Prior decisions (Bicolandia, Cagayan Valley, M.E. Holding) emphasize that tax credit should match the full 20% discount extended.
- The amendments to RA 7432 in 2003 and 2010 now treat the 20% discount as a tax deduction, but these do not apply as the case concerns tax years 1993 and 1994.
- The factual findings of CTA regarding actual discounts given are accepted.
- Petitioner is entitled to tax credits corresponding to actual discounts substantiated: P3,522,123.25 (1993) and P34,211,769.45 (1994).
- Computation of Tax Refunds (Supreme Court)
- For 1993, tax refundable amount computed as P2,289,381.71.
- For 1994, tax refundable amount computed as P22,237,650.34.
Issues:
- What is the proper interpretation of the term "acosta" in Section 4(a) of Republic Act No. 7432 – should the tax credit be based on the acquisition cost of medicines or the full 20% sales discount granted to qualified senior citizens?
- Whether limiting the tax credit to the acquisition cost constitutes an unconstitutional taking without just compensation.
- Whether forcing private establishments to grant the 20% discount without full reimbursement violates due process and equal protection principles.
- Whether prior rulings and the legislative intent support tax credit of full amount of the discount or only the acquisition cost.
Ruling:
- (Subscriber-Only)
Ratio:
- (Subscriber-Only)
Doctrine:
- (Subscriber-Only)